The role of the percutaneous biopsy in the evolving diagnosis and treatment of lung cancer

Barnes, D.; Souza, Carolina A.; Entwisle, James

doi:10.1016/j.crad.2010.06.007

Cited by 7 publications

(3 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our findings suggest that DCE-MRI is better than CT in the discrimination of the solid components of cystic lesions; therefore, the use of DCE-MRI in the determination of the biopsy site in cystic-cavitary lung lesions seems to be reasonable. 20 It can discriminate solid components from impacted secretions, concentrated content and fluid content due to its high resolution and contrast enhancement. Thus, its use prevented unnecessary biopsies by decreasing the number of indeterminate patients and better characterized the biopsy site.…”

Section: Discussionmentioning

confidence: 99%

Added value of DCE‐MRI in the management of cystic‐cavitary lung lesions

et al. 2015

View full text Add to dashboard Cite

Background and objective:We evaluated the added value of dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) to CT in the evaluation of cystic-cavitary lung lesions.We aimed to compare morphological parameters, including wall thickness and inner wall irregularity, and to determine whether DCE-MRI with morphological and dynamic parameters was useful in indeterminate lesions.We also aimed to investigate the added value of DCE-MRI in terms of whether to biopsy, and if so the site of biopsy. Methods: This prospective study included 39 consecutive patients with cystic and/or cavitary lung lesions detected by CT who then underwent additional DCE-MRI. After initial evaluation, the lesions were classified as benign, indeterminate or malignant and the findings of CT and DCE-MRI compared with each other by considering the final diagnosis that was determined by histopathological findings and clinical evaluation and follow up. Results:The mean values for wall thickness obtained by DCE-MRI were lower and the range of wall thickness for indeterminate lesions was narrower than those obtained by CT (5.50-11.50 mm and 5.75-13.50 mm for DCE-MRI and CT), and inner wall irregularity on DCE-MRI was more sensitive in malignant lesions. Also, DCE-MRI obviated biopsy in three benign patients and changed the biopsy site in two patients. Conclusion: Our study suggests that DCE-MRI is helpful in indeterminate cystic-cavitary lung lesions, with morphological and dynamic features. It narrowed the range of wall thickness used for indeterminate lesions, was more sensitive than CT in determining malignant inner wall irregularity, and was also useful in determining the need for and appropriate site of biopsy.

show abstract

Section: Discussionmentioning

confidence: 99%

Added value of DCE‐MRI in the management of cystic‐cavitary lung lesions

et al. 2015

View full text Add to dashboard Cite

show abstract

“…The recent advances in specific chemotherapy and novel targeted therapy (6), and the increasing need for specific pre-surgical diagnosis of histopathological subtypes and molecular analysis (7) have led to an increasing need for larger tissue samples. The choice of FNA or CNB also depends on the clinical setting, the experience of both the radiologist and pathologist, the characteristics of the lesion, and the access route.…”

confidence: 99%

FNA and CNB in the Diagnosis of Pulmonary Lesions: A Single-center Experience on 665 Patients, Comparison between Two Periods

Marchianò

Cosentino

Tolla

et al. 2017

Tumori

View full text Add to dashboard Cite

show abstract

“…Compared with aspiration cytology, core biopsy is preferred and considered superior as it can obtain multiple larger samples for both cytological and histological diagnosis [47,48] and molecular analysis [49,50]. However, increasing biopsy size also increases the risk of complications [13].…”

Section: Tissue Biopsymentioning

confidence: 99%

Diagnosis and Predictive Molecular Analysis of Non–Small-Cell Lung Cancer in the Africa-Middle East Region: Challenges and Strategies for Improvement

Slavík

Asselah

Fakhruddin

et al. 2014

Clinical Lung Cancer

View full text Add to dashboard Cite

Identification of tumour biomarkers provides information on prognosis and guides the implementation of appropriate treatment in patients with many different types of cancer. In nonsmall-cell lung cancer (NSCLC), targeted treatment plans based on biomarker identification are already being utilised in the clinic. However, such predictive molecular testing is not currently a universally employed practice. This is particularly the case in developing countries where lung cancer is increasingly prevalent. In September 2012 and November 2013, a committee of 16 lung cancer experts from Africa and the Middle East met to discuss key issues related to diagnosis and biomarker testing in NSCLC and the implementation of personalised medicine in the region. The committee identified current challenges for effective diagnosis and predictive analysis in Africa and the Middle East. Moreover, strategies to encourage the implementation of biomarker testing were discussed.Ultimately, a practical approach for the effective diagnosis and predictive molecular testing of NSCLC in these regions was derived. Key issues and recommendations arising from the meetings are presented here.Abstract word count: 167 (journal limit: 250)

show abstract

The role of the percutaneous biopsy in the evolving diagnosis and treatment of lung cancer

Cited by 7 publications

References 8 publications

Added value of DCE‐MRI in the management of cystic‐cavitary lung lesions

Added value of DCE‐MRI in the management of cystic‐cavitary lung lesions

FNA and CNB in the Diagnosis of Pulmonary Lesions: A Single-center Experience on 665 Patients, Comparison between Two Periods

Diagnosis and Predictive Molecular Analysis of Non–Small-Cell Lung Cancer in the Africa-Middle East Region: Challenges and Strategies for Improvement

Contact Info

Product

Resources

About